|Mr. Rob Reid||CEO & Director||N/A||N/A||N/A|
|Mr. Jonathan James Held||Chief Financial Officer||N/A||N/A||1986|
|Mr. Maghsoud Dariani||Chief Scientific Officer||N/A||N/A||1953|
|Prof. Michael Barnes||Chief Medical Officer||N/A||N/A||N/A|
|Mr. Gabriel Meneses||VP of Latin America & Caribbean||N/A||N/A||N/A|
Scythian Biosciences Corp. engages in the research and development of cannabinoid-based combination drug therapies for the treatment of concussions and traumatic brain injury. It also develops drug candidates for the treatment of gastro-intestinal inflammatory issues. The company is headquartered in Toronto, Canada.
Scythian Biosciences Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.